Is this you? Create Your Porfile
Avatar

H. Taylor

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where H. Taylor is active.

Explore More

Publication

Featured researches published by H. Taylor.

Lung Cancer | 2008

Routine day 8 blood tests are not necessary for patients with non-small cell lung cancer treated with oral vinorelbine-carboplatin chemotherapy

H.C. Swannie; S. Beesley; R. Shah; S. Lowe; H. Taylor

Lung Cancer | 2016

64 Management of EGFR tyrosine kinase inhibitor associated skin toxicity: a single centre experience

L. Thomas; M. Hadaki; T. Sevitt; R. Shah; R. Burcombe; J. Hall; H. Taylor; S. Beesley; M. Cominos

Lung Cancer | 2016

139 A retrospective review of lung cancer patients receiving whole brain radiotherapy treated at the Kent Oncology Centre (KOC) in 2014, audited against the QUARTZ trial

G. Hegarty; J.Y. Turner; T. Sevitt; R. Burcombe; M. Cominos; H. Taylor; S. Beesley; M. Hadaki; R. Shah; C. Mikropoulos; J. Hall

Lung Cancer | 2015

71: Audit of the epidermal growth factor tyrosine kinase (EGFR) and anaplastic lymphoma kinase (ALK) mutation request pathway in non-squamous non-small cell lung cancer (NSCLC) in Kent

H. Taylor; R. Shah; G. Mccormick; R. Burcombe; S. Beesley; M. Cominos; J. Hall; T. Sevitt

Lung Cancer | 2015

66: Adjuvant chemotherapy dose delivery for completely resected NSCLC in a regional cancer centre: analysis of outcomes by age and comorbidity

S. Wood; R. Li; S. Beesley; J. Brown; M. Cominos; J. Hall; T. Sevitt; R. Shah; H. Taylor; R. Burcombe

Lung Cancer | 2014

145 Radical chemoradiation in non-small cell lung cancer – does the number of chemotherapy cycles matter?

K. Sambasivan; C. Baldry; R. Burcombe; H. Taylor; M. Cominos; S. Beesley; A. Visioli; R. Shah; T. Sevitt

Lung Cancer | 2014

180 A review of treatment of limited stage small cell lung carcinoma at the Kent Oncology Centre

T. Sevitt; A. Shiarli; R. Burcombe; H. Taylor; M. Cominos; S. Beesley; A. Visioli; R. Shah; T. Bird

Lung Cancer | 2014

183 Treating extensive stage small cell lung carcinoma in poor performance status patients – is a high 30 day mortality rate justifiable?

T. Bird; A. Shiarli; R. Burcombe; H. Taylor; M. Cominos; S. Beesley; A. Visioli; R. Shah; T. Sevitt

Lung Cancer | 2013

94 A review of the management of mesothelioma patients who received second line chemotherapy within the Kent Oncology Centre Network

A. Shiarli; A. Georgiou; T. Sevitt; H. Taylor; M. Cominos; S. Beesley; A. Visioli; R. Burcombe

Lung Cancer | 2012

14 Audit of the management of epithelial growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients within the Kent Oncology Centre and its associated units

A. Biondo; S. Beesley; R. Burcombe; M. Cominos; T. Sevitt; H. Taylor; R. Shah

Explore More

Collaboration

Dive into the H. Taylor's collaboration.

Explore More
Researchain Logo
Decentralizing Knowledge